Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

Boehringer Inks Deal with Xencor for Mab Technology

  • Xencor reported a collaboration with Boehringer Ingelheim to optimize therapeutic Mabs with improved clinical performance. Boehringer Ingelheim will apply Xencor’s XmAb™ technology platform, including Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest.

    Xencor says its XmAb Fc domains are designed to enhance the therapeutic properties of antibodies, including sustained half-life, increased structural stability, and greater potency.

    Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional license fees, milestones, and a royalty payment on any products commercialized by Boehringer Ingelheim that incorporate its technology.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »